Mode
Text Size
Log in / Sign up
Phase 3 N=160 Randomized Triple-blind Treatment

Ketamine / Propofol Admixture "Ketofol" at Induction in the Critically Ill Against Etomidate: KEEP PACE Trial

Critical Illness

Enrolled (actual)
160
Serious AEs
7.2%
Results posted
Jan 2019
Primary outcome: Primary: Mean Arterial Pressure — 82.8; 80.9; 81.7; 77.6 mm Hg — p=0.385

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Ketamine / Propofol Admixture (Drug); Etomidate (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Mayo Clinic
Primary completion
Nov 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Mean Arterial Pressure
82.8; 80.9; 81.7; 77.6; 81.9; 75.3 0.385
SECONDARY
Mortality
26; 25 0.605
SECONDARY
Vasopressor Use
1; 5; 12; 18; 57; 64 0.212
SECONDARY
Number of Participants With Adrenal Insufficiency
13; 5; 9; 6
SECONDARY
Mechanical Ventilation Free Days
22; 20 0.911
SECONDARY
Blood Product Transfusions
21; 13; 16; 8; 28; 26 0.069
SECONDARY
Intensive Care Unit Free Days
16; 17 0.994
SECONDARY
Number of Participants Experiencing Delirium Using Confusion Assessment Method in ICU
7; 4 0.233

Summary

The hypothesis of this study is that a Ketamine / Propofol mixture will produce more stable hemodynamics as compared to Etomidate during emergent intubations in the intensive care unit. Patients that require a breathing tube to be placed in the ICU will be randomized to receIve either a Ketamine / Propofol mixture or Etomidate for sedation in order to place the breathing tube.

Eligibility Criteria

Inclusion Criteria

  • 18 years of age or older
  • Surgical or medical intensive care unity patients requiring endotracheal intubation
  • Consulting physician agrees to study plan and will follow drug randomization

Exclusion Criteria

  • Known intracranial pathology
  • Known chronic opiate-dependence
  • Received continuous sedative infusion in the last 24 hours
  • Known severe psychiatric illness
  • Known egg allergies
  • Known contraindication to fentanyl, midazolam, ketamine, propofol or etomidate
  • Intubation in which standard practice is not to use sedation
  • No known documented weight or weight greater than 140 kg or less than 30 kg
  • Prior participation in the study
  • Of childbearing age (18-50) with no known negative pregnancy test on this admission.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02105415). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search